Xilio Therapeutics, Inc. (XLO) Reports Q1 Loss, Beats Revenue Estimates
Xilio Therapeutics (XLO) delivered earnings and revenue surprises of +12.12% and +48.45%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?